JPMorgan Reinstates Insmed (INSM) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Citi cuts Adobe rating on ’rising risk of a hard reset’
- Apple shares slip amid guidance for tightening margins, slowing services growth
Tweet
Share
E-mailGet Alerts INSM Hot Sheet
Price: $104.44 --0%
Rating Summary:
31 Buy, 2 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Rating Summary:
31 Buy, 2 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Join SI Premium – FREE
JPMorgan analyst Jessica Fye reinstates coverage on Insmed (NASDAQ: INSM) with a Overweight rating and a price target of $36.00.
For an analyst ratings summary and ratings history on Insmed click here. For more ratings news on Insmed click here.
Shares of Insmed closed at $24.82 yesterday.
You May Also Be Interested In
- H.C. Wainwright Starts Insmed (INSM) at Buy
- Goldman Sachs Assumes Skyworks Solutions (SWKS) at Sell
- Citi Starts TCL Electronics Holdings (1070:HK) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
